| scholarly article | Q13442814 |
| P50 | author | John K Amory | Q79189384 |
| P2093 | author name string | Alvin M Matsumoto | |
| Stephanie T Page | |||
| Brett T Marck | |||
| Manjiri Dighe | |||
| Janet Gilchriest | |||
| Lianne Hirano | |||
| P2860 | cites work | Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo | Q46974519 |
| Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls | Q71624041 | ||
| Endocrine status in elderly men with lower urinary tract symptoms: correlation of age, hormonal status, and lower urinary tract function. The Prostate Study Group of the Austrian Society of Urology | Q73503624 | ||
| Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group | Q74650177 | ||
| Adverse events associated with testosterone administration | Q24601802 | ||
| Ockham's razor and selective androgen receptor modulators (SARMs): are we overlooking the role of 5alpha-reductase? | Q24675898 | ||
| Effect of dutasteride on the risk of prostate cancer | Q30010961 | ||
| High prevalence of benign prostatic hypertrophy in the community | Q34001274 | ||
| Dose-dependent increase in intratesticular testosterone by very low-dose human chorionic gonadotropin in normal men with experimental gonadotropin deficiency | Q34032007 | ||
| Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline | Q34119261 | ||
| Testosterone supplementation therapy for older men: potential benefits and risks | Q34171397 | ||
| The influence of finasteride on the development of prostate cancer | Q34534815 | ||
| Low serum testosterone and mortality in older men. | Q36360750 | ||
| Drug Insight: 5alpha-reductase inhibitors for the treatment of benign prostatic hyperplasia | Q36590479 | ||
| Androgen biosynthetic pathways in the human prostate | Q37159867 | ||
| Testosterone replacement in men. | Q37204796 | ||
| Should testosterone replacement be given to men with large prostates? | Q43275774 | ||
| Effects of androgen deficiency and replacement on prostate zonal volumes | Q43585997 | ||
| Storage (irritative) and voiding (obstructive) symptoms as predictors of benign prostatic hyperplasia progression and related outcomes | Q44066679 | ||
| Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone | Q44757063 | ||
| Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia | Q45055825 | ||
| Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. | Q45168742 | ||
| Effect of dutasteride on intraprostatic androgen levels in men with benign prostatic hyperplasia or prostate cancer | Q46417821 | ||
| Beneficial effects of testosterone administration on symptoms of the lower urinary tract in men with late-onset hypogonadism: a pilot study | Q46526834 | ||
| Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies | Q46784184 | ||
| Relationship among serum testosterone, sexual function, and response to treatment in men receiving dutasteride for benign prostatic hyperplasia | Q46909952 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | dutasteride | Q424760 |
| prostatic hypertrophy | Q506659 | ||
| testosterone | Q1318776 | ||
| testosterone | Q27863114 | ||
| P304 | page(s) | 191-197 | |
| P577 | publication date | 2011-05-14 | |
| P1433 | published in | Journal of Urology | Q15709979 |
| P1476 | title | Dutasteride reduces prostate size and prostate specific antigen in older hypogonadal men with benign prostatic hyperplasia undergoing testosterone replacement therapy | |
| P478 | volume | 186 |
| Q24564836 | Adverse effects of testosterone replacement therapy: an update on the evidence and controversy |
| Q34207540 | An update on male hypogonadism therapy |
| Q27010093 | Androgens and prostate disease |
| Q57828021 | Benefits and Consequences of Testosterone Replacement Therapy: A Review |
| Q34578805 | Cardiovascular risks and elevation of serum DHT vary by route of testosterone administration: a systematic review and meta-analysis |
| Q53095586 | Dutasteride in men receiving testosterone therapy: a randomised, double-blind study. |
| Q43842409 | Effects of dutasteride on lower urinary tract symptoms and general health in men with benign prostatic hypertroplasia and hypogonadism: a prospective study |
| Q34276286 | Emerging medication for the treatment of male hypogonadism |
| Q38064269 | Hormonal manipulation of benign prostatic hyperplasia |
| Q49629325 | Influence of dutasteride treatment on serum hormone levels and aging male symptoms in patients with benign prostatic enlargement |
| Q33816511 | Musculoskeletal and prostate effects of combined testosterone and finasteride administration in older hypogonadal men: a randomized, controlled trial. |
| Q37057953 | Stable Intraprostatic Dihydrotestosterone in Healthy Medically Castrate Men Treated With Exogenous Testosterone |
| Q38528388 | Testosterone Replacement Therapy on the Natural History of Prostate Disease |
| Q36020300 | Testosterone replacement in hypogonadal men alters the HDL proteome but not HDL cholesterol efflux capacity |
| Q47215640 | Testosterone replacement therapy and prostate health |
| Q48060016 | Testosterone treatment of men with mild cognitive impairment and low testosterone levels |
| Q38111255 | The effect of 5α-reductase inhibitors on prostate growth in men receiving testosterone replacement therapy: a systematic review and meta-analysis |
Search more.